FLT3 and acute myeloid leukemia: The first generation FLT3 inhibitor midostaurin and more potent second generation gilteritinib are FDA-approved for marketing in this setting and have been shown to prolong survival of patients with FLT3-mutated AML, either in combination with standard chemotherapy as initial treatment (midostaurin) or as salvage therapy (gilteritinib) [4,5].